Skip to main content
Premium Trial:

Request an Annual Quote

BioNTech, Shuwen Ink Chinese Distribution Deal for Breast Cancer Stratification Test

NEW YORK (GenomeWeb) – Germany's BioNTech Diagnostics and Shuwen Biotech said today that they have signed a deal to commercialize BioNTech's molecular breast cancer stratification test MammaTyper in China.

According to BioNTech, MammaTyper is a CE-IVD marked test that measures expression levels of four genes in breast cancer tissue via RT-qPCR in order to stratify tumor samples into four subtypes: luminal A-like, luminal B-like/HER2 negative, luminal B-like/HER2 positive, HER2 positive/non-luminal, and triple-negative/ductal.

Under the terms of the agreement, Deqing, China-based Shuwen will undertake clinical studies to obtain regulatory approval of MammaTyper in China, where it will be the test's exclusive distributor. Financial and other terms were not disclosed.

"This is a strategic long-term cooperation to establish and strengthen our position in the Chinese oncology diagnostics market and will pave the way for launching our own personalized immunotherapies for the treatment of cancer in China," Sierk Poetting, BioNTech CFO and managing director of BioNTech Diagnostics, said in a statement.

BioNTech Diagnostics is a wholly owned subsidiary of BioNTech, a privately owned cancer drug developer that was founded in 2008.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.